Bayer's Summer of Reckoning: Supreme Court Victory, a Delayed Hearing, and Record Debt Test a 104% Rally
Published on 07/06/2026 at 11:13 | Redaktion boerse-global.de
Bayer’s shares have more than doubled over the past twelve months, climbing 103.57% as of last Friday’s close at €53.04 — and touching €53.12 in recent sessions. The stunning advance has been fuelled by a triple dose of positive news: a US Supreme Court ruling that blocks states from imposing independent cancer warnings on pesticides, the creation of a separate US entity to house glyphosate operations, and a fresh antidumping complaint against Chinese imports. Yet with the stock now trading within a whisker of its 52-week high of €53.86, the euphoria is colliding with a host of technical and legal risks that could determine whether the rally has further to run.
The Supreme Court delivered its judgment on 26 June, overturning a Missouri state court decision and effectively neutralising thousands of future lawsuits alleging inadequate warning labels on the weedkiller Roundup. Days later, Bayer completed the spin-off of its US glyphosate business into a new subsidiary, Ruveon LLC, officially effective 1 July 2026. Shortly after that, the group filed an antidumping petition in Washington, seeking tariffs on cut-price glyphosate imports from China. Separately, the US Food and Drug Administration has granted accelerated review to Bayer’s stroke prevention candidate Asundexian, with pivotal results due in the second half of 2026.
But just as the legal landscape appeared to brighten, a court in Missouri threw a spanner in the works. The final approval hearing for Bayer’s $7.25 billion global settlement of Roundup claims — originally scheduled for early July — has been postponed. The new date is 19 August 2026. That delay, while not derailing the deal itself, injects a fresh dose of uncertainty into a stock that is already technically overheated. The relative strength index has surged to 85.2, a level that historically signals an imminent pullback. The shares now trade roughly 43% above their 200-day moving average of €37.11, and the annualised volatility stands at nearly 63%.
Should investors sell immediately? Or is it worth buying Bayer?
On the financial front, the picture remains sobering. Bayer carries net debt of €32.5 billion, and the group expects to shell out €5 billion in litigation costs this year alone. The Supreme Court ruling may block future warning-label claims, but it does not erase existing liabilities: the mammoth settlement still requires judicial sign-off, and plaintiffs can still sue over defective design or negligence. Analysts at Deutsche Bank, however, see reason for optimism. On 2 July they raised their price target on Bayer from €45 to €60 and upgraded the stock from “hold” to “buy”, citing the structural reduction in legal risk.
From a technical perspective, the stock’s vertical ascent is its own worst enemy. The 15.76% weekly gain and 47.54% monthly surge have stretched valuations to a point where any disappointment could trigger a sharp reversal. The first key support sits at the 50-day moving average of €38.86, a full 27% below current levels. If the August hearing produces a negative outcome, the overbought conditions could act as an accelerant on the way down.
Investors will have to navigate a critical two-week window in August. Bayer publishes its quarterly results at the start of the month, giving management a chance to demonstrate that free cash flow is stabilising. Then, on 19 August, the Missouri court will either approve the settlement or inject fresh doubt. A green light would provide fundamental backing for the rally; a rejection could spark a violent sell-off. For now, the stock is caught between a Supreme Court-driven tailwind and a technical setup that rarely ends in a smooth ride higher.
Ad
Bayer Stock: New Analysis - 6 July
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
